What are the current guidelines for annual low‑dose computed tomography (LDCT) lung‑cancer screening, including age range, pack‑year threshold, smoking status, and discontinuation criteria?

Current Guidelines for Lung Cancer Screening

The American Cancer Society (2024) and USPSTF (2021) recommend annual low-dose computed tomography (LDCT) screening for adults aged 50–80 years with ≥20 pack-years of smoking history who currently smoke or have quit within the past 15 years. 1, 2

Eligibility Criteria

Age Range

• Start screening at age 50 years (expanded from the previous 55-year threshold) 1, 2
• Stop screening at age 80 years for most guidelines 3, 2
• The 2024 ACS guideline represents the most recent update, removing the years-since-quitting criterion while maintaining the age 50–80 range 1

Smoking History Requirements

• Minimum 20 pack-years of smoking exposure (one pack per day for 20 years, or two packs per day for 10 years) 1, 2
• Currently smoking OR quit within the past 15 years for USPSTF criteria 2
• The 2024 ACS guideline eliminates the 15-year quit criterion entirely—former smokers remain eligible regardless of years since quitting, as long as they meet age and pack-year thresholds 1

Alternative High-Risk Criteria (NCCN Category 2A)

• Adults ≥50 years with ≥20 pack-years PLUS one additional risk factor qualify for screening: 4, 5
  • Personal history of cancer (lung, lymphoma, head/neck, or other smoking-related cancers)
  • Chronic lung disease (COPD, pulmonary fibrosis)
  • First-degree relative with lung cancer
  • Occupational carcinogen exposure (asbestos, arsenic, chromium, nickel, silica)
  • Radon exposure

Screening Protocol

Modality and Frequency

• Annual LDCT without IV contrast is the only validated screening test 4, 6
• One-time screening is never appropriate—the mortality benefit requires annual screening 4
• Chest radiography (X-ray) does NOT reduce lung cancer mortality and must not be used for screening 4, 6

Technical Specifications

• Multidetector CT scanner with 120–140 kVp, 20–60 mAs 6
• Average effective radiation dose ≤1.5 mSv 6
• Collimation ≤2.5 mm 6

Discontinuation Criteria

Stop screening when any of the following occur: 3, 6, 2

• Age >80 years (though NCCN allows continuation if fit for curative surgery) 4, 5
• Quit smoking >15 years ago (USPSTF criterion; ACS 2024 removes this) 2, 1
• Health problems that substantially limit life expectancy
• Unable or unwilling to undergo curative lung surgery
• Requires home oxygen supplementation 3

Implementation Requirements

Mandatory Components

• High-quality screening centers with multidisciplinary teams (thoracic radiology, pulmonary medicine, thoracic surgery) are required 3, 4, 7
• Shared decision-making discussion covering benefits (≈20% mortality reduction), harms (false positives, overdiagnosis in 10–12% of cases, radiation exposure), and limitations 3, 4, 2
• Vigorous smoking cessation counseling is the single most effective intervention to reduce lung cancer risk—current smokers must receive evidence-based cessation counseling and referral to cessation programs 3, 8, 4
• Screening is NOT a substitute for smoking cessation 3, 8

Nodule Management

• Nodules ≥5 mm require 3-month follow-up LDCT 6
• Nodules ≥15 mm require immediate diagnostic evaluation 6
• Follow-up scans should be limited LDCT covering only the nodule area 6

Key Divergences Between Guidelines

The 2024 ACS guideline differs from USPSTF 2021 in one critical way: it eliminates the 15-year quit criterion, meaning former heavy smokers remain eligible indefinitely based on age and pack-year history alone 1. This reflects evidence that lung cancer risk remains elevated beyond 15 years of cessation 9. The USPSTF maintains the 15-year cutoff 2.

The NCCN expanded criteria (age ≥50, ≥20 pack-years plus one risk factor) capture significantly more at-risk individuals—using only the narrow NLST criteria (age 55–74, ≥30 pack-years) would identify only 27% of patients later diagnosed with lung cancer 4, 5.

Common Pitfalls to Avoid

• Never screen individuals <50 years, regardless of smoking history or family history 4
• Never use chest X-ray for screening—it is proven ineffective 4, 6
• Never order standard-dose CT—only low-dose protocols are appropriate 4
• Never screen patients with <20 pack-years without additional risk factors—this shifts the benefit-harm balance unfavorably 4
• Do not screen symptomatic patients—they require diagnostic testing, not screening 6
• Do not screen patients with comorbidities precluding curative surgery 1, 2

Evidence Strength

The 2024 ACS guideline 1 represents the most recent high-quality update, based on moderate-quality evidence and judged sufficient for a strong recommendation. The 2021 USPSTF expansion 2 increased screening eligibility from 14.1% to 20.6–23.6% of the population and reduced sex/race disparities while maintaining a favorable benefit-to-harm ratio 10. The National Lung Screening Trial (NLST) demonstrated a 20% reduction in lung cancer mortality with annual LDCT 3, 4.